Key Takeaways
- CRSP shares plummeted as much as 11.59% during Friday’s session, bottoming at $51.21
- First-quarter results disappointed significantly: EPS came in at -$1.37 compared to consensus of -$1.15; revenue reached only $0.86M versus $4.72M forecast — representing a 97.8% year-over-year decline
- Regeneron received approval for Otarmeni, a gene therapy that will be provided at no cost to qualifying U.S. patients, creating potential pricing challenges for Casgevy
- Chief Executive Officer Samarth Kulkarni offloaded 10,349 shares on March 16; company insiders have collectively sold 51,828 shares in the last ninety days
- Wall Street maintains a consensus “Moderate Buy” recommendation with an average target price of $64.53
CRISPR Therapeutics ($CRSP) experienced a challenging trading session on Friday. Shares declined as much as 11.59%, touching an intraday low of $51.21, ultimately closing near $51.04 — a significant drop from the previous closing price of $55.18. Trading volume registered approximately 1.36 million shares, roughly 27% lighter than typical activity.
The sharp decline stemmed from two concurrent developments: disappointing quarterly financial results and emerging competitive headwinds from Regeneron.
Regarding financial performance, CRISPR disclosed quarterly earnings per share of -$1.37, falling short of the analyst consensus projection of -$1.15. Quarterly revenue registered merely $0.86 million — dramatically below the anticipated $4.72 million. This represents a staggering 97.8% decline compared to the same period last year, shocking market participants.
The biotechnology firm’s return on equity remains deeply negative at -26.31%, while its net margin continues to reflect substantial losses. Wall Street forecasters currently project full-year EPS of -$4.93.
Regeneron’s No-Cost Gene Therapy Creates Competitive Headwinds
The second major factor weighing on shares involves Regeneron’s recent regulatory approval. The pharmaceutical giant secured clearance for Otarmeni, a gene therapy product it intends to distribute without charge to qualifying U.S. patients. This represents a significant challenge to the broader gene-editing industry.
CRISPR’s primary commercial product, Casgevy — co-developed alongside Vertex Pharmaceuticals — commands a $2.2 million list price. Investor concerns center on whether Regeneron’s no-cost distribution strategy might trigger broader pricing pressures throughout the sector, complicating the value proposition for high-priced, single-dose treatments.
Casgevy achieved historic status as the first CRISPR-based treatment to secure FDA authorization, representing a groundbreaking scientific achievement. However, commercial adoption has progressed more slowly than anticipated, and the Regeneron development introduces additional uncertainty regarding future revenue generation.
Executive Stock Sales Compound Investor Concerns
Recent insider transactions have contributed to negative sentiment surrounding the stock. Chief Executive Officer Samarth Kulkarni divested 10,349 shares on March 16 at approximately $48.26 per share, decreasing his ownership position by roughly 4%. General Counsel James Kasinger sold 3,450 shares during the same trading day.
Cumulatively over the past ninety days, company insiders have disposed of 51,828 shares, generating approximately $2.58 million in proceeds. Current insider ownership stands at 4.30% of outstanding shares.
While such transactions aren’t necessarily uncommon among biotechnology executives managing stock-based compensation, the timing amplifies investor apprehension about the company’s near-term prospects.
Analyst sentiment remains cautiously optimistic despite recent setbacks. Bank of America maintains a Buy recommendation with an $89 price objective. Needham assigns a Buy rating with an $82 target. TD Cowen holds a neutral stance with a Hold rating and $45 target. Citizens JMP rates the stock Market Outperform with an $80 valuation. The Wall Street consensus lands at Moderate Buy, featuring an average price target of $64.53 — substantially above current trading levels.
Technical indicators show the stock’s 50-day moving average at $52.68 and the 200-day moving average at $55.70. The company maintains a market capitalization of approximately $4.90 billion with a beta coefficient of 1.80.
Current price action positions CRSP around $51, continuing to trade beneath both critical moving average benchmarks.
Get 3 Free Stock Ebooks
Discover top-performing stocks in AI, Crypto, and Technology with expert analysis.
- Top 10 AI Stocks - Leading AI companies
- Top 10 Crypto Stocks - Blockchain leaders
- Top 10 Tech Stocks - Tech giants
